Parambir S Dulai (P S Dulai, Parambir Dulai)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 43

Top Topics

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

Inflammatory bowel diseases

bioRxiv : the preprint server for biology

Crohn's & colitis 360

This page only lists publications with an associated author ORCID identifier.

Publications

Sailish Honap, Vipul Jairath, Bruce E Sands, Parambir S Dulai, Marjorie Costa Argollo, Laurent Peyrin Biroulet
Acute severe ulcerative colitis trials: the past, the present and the future. Gut (2024)
Carlos G Gonzalez, Toer W Stevens, Bram Verstockt, David J Gonzalez, Geert R A M D'Haens, Parambir S Dulai
Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab. Inflammatory bowel diseases (2024)
Carlos G Gonzalez, Toer W Stevens, Bram Verstockt, David J Gonzalez, Geert R A M D'Haens, Parambir S Dulai
Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab. Inflammatory bowel diseases (2024)
Carlos G Gonzalez, Toer W Stevens, Bram Verstockt, David J Gonzalez, Geert R A M D'Haens, Parambir S Dulai
Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab. Inflammatory bowel diseases 30 (9) (2024)
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Chia-Yun Hsu, Caitlin Tribelhorn, Pedro Belda Ferre, Allison Ea, MacKenzie Bryant, Jocelyn Young, Hannah C Carrow, William J Sandborn, Parambir S Dulai, Mamata Sivagnanam, David T Pride, Rob Knight, Hiutung Chu
Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv : the preprint server for biology (2023)
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Chia-Yun Hsu, Caitlin Tribelhorn, Pedro Belda Ferre, Allison Ea, MacKenzie Bryant, Jocelyn Young, Hannah C Carrow, William J Sandborn, Parambir S Dulai, Mamata Sivagnanam, David T Pride, Rob Knight, Hiutung Chu
Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv : the preprint server for biology (2023)
Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula
Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy. Inflammatory bowel diseases (2023)
Gursimran S Kochhar, Aakash Desai, Francis A Farraye, Raymond K Cross, Sandra El-Hachem, Parambir S Dulai, Miguel Regueiro
Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study. Alimentary pharmacology & therapeutics (2023)
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Chia-Yun Hsu, Caitlin Tribelhorn, Pedro Belda Ferre, Allison Ea, MacKenzie Bryant, Jocelyn Young, Hannah C Carrow, William J Sandborn, Parambir S Dulai, Mamata Sivagnanam, David T Pride, Rob Knight, Hiutung Chu
Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv : the preprint server for biology (2023)
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Chia-Yun Hsu, Caitlin Tribelhorn, Pedro Belda Ferre, Allison Ea, MacKenzie Bryant, Jocelyn Young, Hannah C Carrow, William J Sandborn, Parambir S Dulai, Mamata Sivagnanam, David T Pride, Rob Knight, Hiutung Chu
Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv : the preprint server for biology (2023)
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Chia-Yun Hsu, Caitlin Tribelhorn, Pedro Belda Ferre, Allison Ea, MacKenzie Bryant, Jocelyn Young, Hannah C Carrow, William J Sandborn, Parambir S Dulai, Mamata Sivagnanam, David T Pride, Rob Knight, Hiutung Chu
Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv : the preprint server for biology (2023)
Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula
Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index. Inflammatory bowel diseases (2023)
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Chia-Yun Hsu, Caitlin Tribelhorn, Pedro Belda Ferre, Allison Ea, MacKenzie Bryant, Jocelyn Young, Hannah C Carrow, William J Sandborn, Parambir S Dulai, Mamata Sivagnanam, David T Pride, Rob Knight, Hiutung Chu
Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv : the preprint server for biology (2023)
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Chia-Yun Hsu, Caitlin Tribelhorn, Pedro Belda Ferre, Allison Ea, MacKenzie Bryant, Jocelyn Young, Hannah C Carrow, William J Sandborn, Parambir S Dulai, Mamata Sivagnanam, David T Pride, Rob Knight, Hiutung Chu
Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv : the preprint server for biology (2023)
Khushdeep Dharni, Arshdeep Singh, Sonika Sharma, Vandana Midha, Dr Kirandeep Kaur, Ramit Mahajan, Parambir S Dulai, Ajit Sood
Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019). Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology (2023)
Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn's Disease. Inflammatory bowel diseases (2022)
Emily Chu Lee Wong, Parambir S Dulai, Neeraj Narula
Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system" by Gui et al . Gut (2022)
Parambir S Dulai, Emily C L Wong, Walter Reinisch, Jean Frederic Colombel, John K Marshall, Neeraj Narula
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflammatory bowel diseases 28 (10) (2022)
Parambir S Dulai, Yaping Wan, Zhongwen Huang, Michelle Luo
Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn's Disease. Crohn's & colitis 360 4 (4) (2022)
Neeraj Narula, Emily Chu Lee Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. Inflammatory bowel diseases (2022)
Ariela K Holmer, Brigid S Boland, Siddharth Singh, Jennifer Neill, Helen Le, Ara Miralles, Angelina E Collins, William J Sandborn, Parambir S Dulai
A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. Inflammatory bowel diseases (2022)
Cara Pray, Emily Chu Lee Wong, Achuthan Aruljothy, Parambir S Dulai, John K Marshall, Walter Reinisch, Neeraj Narula
Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis. Inflammatory bowel diseases (2022)
Emily Chu Lee Wong, Arif Yusuf, Jagoda Pokryszka, Parambir S Dulai, Jean Frederic Colombel, John K Marshall, Walter Reinisch, Neeraj Narula
Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn's Disease. Inflammatory bowel diseases (2022)
Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease. Inflammatory bowel diseases (2022)
Parambir S Dulai, Yaping Wan, Zhongwen Huang, Michelle Luo
Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn's Disease. Crohn's & colitis 360 4 (4) (2022)
Yousaf Bashir Hadi, Parambir S Dulai, Justin Kupec, Nabeeha Mohy-Ud-Din, Vipul Jairath, Francis A Farraye, Gursimran S Kochhar
Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: propensity matched research network analysis. Alimentary pharmacology & therapeutics 55 (2) (2021)
Sushrut Jangi, Hyuk Yoon, Parambir S Dulai, Mark Valasek, Brigid Boland, Vipul Jairath, Brian G Feagan, William J Sandborn, Siddharth Singh
Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply. Alimentary pharmacology & therapeutics 53 (8) (2021)
Sushrut Jangi, Hyuk Yoon, Parambir S Dulai, Mark Valasek, Brigid S Boland, Vipul Jairath, Brian G Feagan, William J Sandborn, Siddharth Singh
Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Alimentary pharmacology & therapeutics 52 (6) (2020)
Matthew Bohm, Ronghui Xu, Yiran Zhang, Sashidhar Varma, Monika Fischer, Gursimran Kochhar, Brigid Boland, Siddharth Singh, Robert P Hirten, Ryan C Ungaro, Eugenia Shmidt, Karen Lasch, Vipul Jairaith, David Hudesman, Shannon Chang, Dana Lukin, Arun Swaminath, Bruce E Sands, Jean Frederic Colombel, Sunanda Kane, Edward V Loftus, Bo Shen, Corey A Siegel, William J Sandborn, Parambir S Dulai, null null
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary pharmacology & therapeutics 52 (4) (2020)
Parambir S Dulai, Vipul Jairath, Reena Khanna, Christopher Ma, Kelly P McCarrier, Mona L Martin, Claire E Parker, Joan Morris, Brian G Feagan, William J Sandborn
Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Alimentary pharmacology & therapeutics 51 (11) (2020)
Edward Yang, Nicola Panaccione, Natalie Whitmire, Parambir S Dulai, Niels Vande Casteele, Siddharth Singh, Brigid S Boland, Angelina Collins, William J Sandborn, Remo Panaccione, Robert Battat
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Alimentary pharmacology & therapeutics 51 (11) (2020)
Siddharth Singh, Jihoon Kim, Wenhong Zhu, Parambir S Dulai, William J Sandborn, Vipul Jairath
No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Alimentary pharmacology & therapeutics 52 (3) (2020)
Robert Battat, Niels Vande Casteele, Rish K Pai, Zhongya Wang, Guangyong Zou, John W D McDonald, Marjolijn Duijvestein, Jenny Jeyarajah, Claire E Parker, Tanja Van Viegen, Sigrid A Nelson, Brigid S Boland, Siddharth Singh, Parambir S Dulai, Mark A Valasek, Brian G Feagan, Vipul Jairath, William J Sandborn
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Alimentary pharmacology & therapeutics 52 (10) (2020)
Gursimran S Kochhar, Aakash Desai, Aslam Syed, Abhinav Grover, Sandra El Hachem, Heitham Abdul-Baki, Preethi Chintamaneni, Elie Aoun, Sowjanya Kanna, Dalbir S Sandhu, Siddharth Singh, Bo Shen, Edward V Loftus, Parambir S Dulai
Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications. Alimentary pharmacology & therapeutics 51 (11) (2020)
Edward Yang, Nicola Panaccione, Natalie Whitmire, Parambir S Dulai, Niels Vande Casteele, Siddharth Singh, Brigid S Boland, Angelina Collins, William J Sandborn, Remo Panaccione, Robert Battat
Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. Alimentary pharmacology & therapeutics 52 (3) (2020)
Parambir S Dulai
Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Authors' reply. Alimentary pharmacology & therapeutics 51 (7) (2020)
Parambir S Dulai, Laura E Raffals, David Hudesman, Michael Chiorean, Raymond Cross, Tasneem Ahmed, Michael Winter, Shannon Chang, David Fudman, Charlotte Sadler, Ernest L Chiu, Frank L Ross, Gary Toups, M Hassan Murad, Kinjal Sethuraman, James R Holm, Renie Guilliod, Benjamin Levine, Jay C Buckey, Corey A Siegel
A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. Alimentary pharmacology & therapeutics 52 (6) (2020)
Parambir S Dulai, Aurelien Amiot, Laurent Peyrin Biroulet, Vipul Jairath, Melanie Serrero, Jerome Filippi, Siddharth Singh, Benjamin Pariente, Edward V Loftus, Xavier Roblin, Sunanda Kane, Anthony Buisson, Corey A Siegel, Yoram Bouhnik, William J Sandborn, Karen Lasch, Maria Rosario, Brian G Feagan, Daniela Bojic, Caroline Trang-Poisson, Bo Shen, Romain Altwegg, Bruce E Sands, Jean Frederic Colombel, Franck Carbonnel, null null
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Alimentary pharmacology & therapeutics 51 (5) (2019)
Siddharth Singh, Larry W Stitt, Guangyong Zou, Reena Khanna, Parambir S Dulai, William J Sandborn, Brian G Feagan, Vipul Jairath
Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. Alimentary pharmacology & therapeutics 49 (9) (2019)
Parambir S Dulai, Siddharth Singh, Vipul Jairath, Christopher Ma, Neeraj Narula, Niels Vande Casteele, Laurent Peyrin Biroulet, Severine Vermeire, Geert D'Haens, Brian G Feagan, William J Sandborn
Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Alimentary pharmacology & therapeutics 51 (4) (2019)
Siddharth Singh, Parambir S Dulai, Niels Vande Casteele, Robert Battat, Mathurin Fumery, Brigid S Boland, William J Sandborn
Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Alimentary pharmacology & therapeutics 50 (8) (2019)
Christopher Ma, Robert Battat, Parambir S Dulai, Claire E Parker, William J Sandborn, Brian G Feagan, Vipul Jairath
Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 79 (12) (2019)
S Kurnool, N H Nguyen, J Proudfoot, Parambir S Dulai, B S Boland, N Vande Casteele, E Evans, E L Grunvald, A Zarrinpar, William J Sandborn, Siddharth Singh
High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Alimentary pharmacology & therapeutics 47 (11) (2018)